Financial Markets Research: Renovis, Inc.'s NXY-059

Summary

Introduction

Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.

Highlights

Pending results from the Phase III SAINT-II trial expected later this year, we estimate that NXY-059's safety profile and the modifications to the Phase III trial could support its eventual approval in early 2008, leading to blockbuster potential by 2012.If approved in early 2008, we expect that Renovis and AstraZeneca's NXY-059 would be rapidly utilized in eligible patients due to its strong safety profile and lack of alternative options.As a result, we forecast worldwide NXY-059 revenues that fall only slightly below long-term Wall Street consensus.

Scope

• Analyzes the regulatory and commercial potential for RNVS' NXY-059, a novel agent that aims to reduce brain damage post-ischemic stroke
• Datamonitor interviewed four neurologists familiar with NXY-059 and its clinical data regarding its potential for the treatment of ischemic stroke

Reasons to Purchase

• Understand the regulatory and commercial potential for Renovis' NXY-059 through in-depth analysis, based on interviews with leading experts
• Anticipate likely changes in the future market dynamics for stroke therapies if approval of NXY-059 occurs

Content